Melanoma research continues to lead the way in new immunotherapies
For recipient of the ESMO Lifetime Achievement Award, Prof. John Haanen, melanoma research has provided him with a career full of innovation, but there is always more to explore
Do young patients benefit from immune checkpoint inhibitors?
First evidence for the efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population
Is gender equity still an issue in oncology?
At the ESMO Congress 2024, the ESMO Women for Oncology (W4O) Committee is presenting new findings on female representation in leadership positions
Tumour-agnostic oncology – time has come to re-think clinical research
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
Cancer in old patients: geriatric assessment and management plays a crucial role to provide personalised care
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
Cancer Control Principles
How to mark a tangible impact in cancer control
Recent research shows that tailored strategies and political commitment can revert current epidemiology trends of cancer
First gene engineered T-cell therapy for solid tumours confirmed to be a promising tool
The positive results of the SPEARHEAD-1 trial which showed durable responses of afamitresgene autoleucel in unresectable or metastatic synovial sarcoma granted FDA accelerated approval
Tailoring care for LGBTQ patients with cancer – a long way ahead?
With a recent survey in collaboration with SIOPE and the recognition of LGBTQ as a specific patient population in the recommendations for a Global Curriculum in Medical Oncology, ESMO is at the forefront of a more inclusive oncology
Cancer Prevention
The sunscreen dilemma – how to make skin cancer prevention environmentally friendly?
The use of sunscreens is essential to protect the skin from UV exposure, but they may enter waterways damaging the ecosystem
First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors